GalNAc-L96：高效RNA靶向递送的关键分子 ...

祖先拼命进化出的碳水消化能力，你现在竟然要戒了？

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

两款疫苗临床前数据显示，其免疫原性强、安全性良好。

悦康药业在政策与市场的双重驱动下，以“创新药+国际化+智能化”为核心引擎，不断突破技术难题，推进中药创新与现代科技融合，积极开拓全球市场，向着全球价值链高端稳步攀升，也为中国医药产业转型升级提供了宝贵经验。

3月14日，悦康药业发布2024年全年业绩报告。报告显示，公司全年归母净利润达1.24亿元，研发投入4.22亿元，占营业收入比例11.16%，全年新增专利授权63项，累计专利达317项，构建起技术积累与管线布局的双重优势。

After hours: March 14 at 5:37:22 PM EDT Loading Chart for SLN ...

mid-2025 update on optimization for GalNAc delivery Continue to execute on partnership with Lilly, with potential data updates, milestone income from the existing partnership, and an option to ...

The results come from the phase 1b/2a RestorAATion-2 study of WVE-006, a GalNAc-conjugated oligonucleotide that is designed to correct a mutation in mRNA associated with AATD that prevents ...

We remain committed to driving forward the next era of transformative RNA editing therapeutics for patients in need.” mid-2025 update on optimization for GalNAc delivery Continue to execute on ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...